The Progressive Reduction in the Ovarian Reserve in Young Women After Anticancer Treatment
In recent years, serum inhibin B and anti-Mülle-rian hormone (AMH) measurements have been used as sensitive direct markers of the ovarian reserve, even for predicting age at menopause. Inhibin B is a product of granulosa cells in antral follicles; it suppresses FSH (follicle-stimulating hormone) production in the hypothalamic-pituitary-ovarian axis. During the menstrual cycle, the level of inhibin B changes, being the highest in the early follicular phase and at the time of ovulation. AMH is produced by granulosa cells of the primary, preantral and little antral follicles. The serum level of AMH during the menstrual cycle is relatively stable and does not seem to remain under hormonal infl uence. Serum AMH and inhibin B levels are related to age and number of antral follicles. The measurement of inhibin B and AMH can be very helpful for predicting ovarian failure and premature menopause in women treated for diff erent neoplasms [ 6 -8 ] . We previously found lower AMH levels only in girls receiving infradiaphragmatic radiotherapy, whereas in
Introduction

▼
Composed anticancer treatment, successfully used in children in the last 40 years, has caused a prolonged survival, but it has also provoked different systemic late eff ects in cancer survivors. The gonads are susceptible to damage, particularly by the alkylating agents (cyclophosphamide, melphalan, busulphan, procarbazine) and/ or radiation to the areas of the ovaries or testicles [ 1 -3 ] . This kind of treatment damages rapidly dividing cells, leading to spermatogenesis deterioration in men and depletion of oocytes in women. Development of infertility or impaired fertility diff ers between sexes. In men, spermatogenesis can be disturbed during and after cytotoxic anticancer treatment due to depletion of the proliferating germ-cell pool, which results in infertility or subfertility. In women, gonadotoxic therapy initiates deterioration of ovarian function, damages the primordial follicles in the ovaries, thus leading to premature menopause [ 4 , 5 ] .
Anticancer treatment can disturb gonadal function and deplete the primordial follicle pool, leading to premature menopause. We made a prospective analysis of serum hormone levels in young female cancer survivors who had been treated during childhood and adolescence. Serum anti-Müllerian hormone (AMH) as a marker of ovarian reserve, FSH, LH, and estradiol were measured in 33 women treated previously (6-11 years earlier) for Hodgkin Lymphoma, solid tumours, and after bone marrow transplantation, and in 34 healthy controls. The group of survivors was divided according to the risk of gonadotoxicity into the low risk and median risk group (LR + MR), and into the high risk (HR) group. The measurements were repeated after 5 years. In the HR group, AMH levels were signifi cantly lower than in controls (p = 0.001) and in the LR + MR group (p = 0.006) at the time of the fi rst examination fell progressively after 5 years (p = 0.03), whereas elevated FSH values (p = 0.053) increased (p = 0.001).
Unchanged LH values in the fi rst measurement rose in the second one (p = 0.001). In the LR + MR group, the levels of AMH and FSH were normal (compared to the control) at baseline, but after 5 years serum AMH decreased (p = 0.027) and FSH increased (p = 0.008). Our fi ndings indicate that anticancer treatment during childhood and adolescence is associated with a serious, progressive risk of ovarian failure. It is necessary to inform female cancer survivors, especially the high risk patients, about the risk of premature menopause. all the study groups of survivors the levels of AMH, LH (luteinizing hormone), and FSH did not diff er as compared to healthy peers [ 9 ] . In the present prospective study, we assess the ovarian reserve in part of the same group of cancer survivors after a 5-year period.
Patients and Methods
▼
Thirty-three young women treated previously (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) 
Hormone level measurements
Serum concentrations of FSH (normal values: 2.8-10 mIU/ml), LH (normal values: 1.1-11.6 mIU/ml), and E2 (normal values: 12.5-166 pg/ml) were performed in the same laboratory using the commercially available immunoenzymatic kits; serum AMH levels (normal values: 2.2-4 ng/ml) were performed with the EIA AMH/MIS kit (Immunotech, Beckman Coulter Company, Marseille, France). All hormonal measurements were performed in the early follicular phase (2-4 days of menstrual cycle) and stored at − 80 °C. Only 5 patients accepted an ovarian transvaginal ultrasound examination at the fi rst time to determine the ovarian volume and the number of small antral follicles; we decided not to present the results of these measurements. The study was approved by the local Medical Ethics Committee. Hormone measurements were made after obtaining informed consent from the patients.
Statistical analysis
Results are expressed as mean ± standard deviation. The normality of data distribution was assessed by the Shapiro-Wilk test. For normally distributed variables the paired and unpaired Student's t -test was used and otherwise Mann-Whitney U-test and Wilcoxon test for pairs. Results were considered to be statistically significant if p < 0.05. Statistical analysis was performed with the use of the SPSS statistical package.
Results
▼
At the time of the fi rst analysis, the mean values of AMH were lower in the high risk group (HR) ( x = 2.06 ng/ml ± 1.72, min: 0.25 ng/ml, max: 7.66 ng/ml) as compared to the median risk (MR) and low risk (LR) group taken together (4.10 ng/ml ± 2.34, min: 1.04 ng/ml, max: 8.61 ng/ml), p = 0.006, and to the control group (3.79 ng/ml ± 1.25), p = 0.001. There was no diff erence between the LR + MR group and the control, p = 0.614 ( • ▶ Fig. 1 ).
The mean values of FSH were elevated (on the limit of statistical signifi cance) in the HR group (19.53 mIU/ml ± 31.73, min: 3.2 mIU/ml, max: 61.3 mIU/ml) as compared to the control (5.36 mIU/ml ± 1.9) p = 0.053, whereas they were normal in the LR + MR group (6.72 mIU/ml ± 2.73, min: 2.2 mIU/ml, max:
9.7 mIU/ml), p = 0.06 ( • ▶ Fig. 2 ).
The mean values of LH did not diff er statistically between the HR (7.85 mIU/ml ± 8.86, min: 1.0 mIU/ml, max: 29.1 mIU/ml), p = 0.957, LR + MR risk group (4.79 mIU/ml ± 4.0, min: 1 mIU/ml, max: 12 mIU/ ml), and control (5.26 mIU/ml ± 4.1), p = 0.728 ( • ▶ Fig. 3 ). Similarly, we observed no diff erences in E2 levels between the control (53.32 pg/ml ± 41.15) and the HR group (44.17 pg/ml ± 38.72, min: 5.0 pg/ml, max: 130.7 pg/ml) p = 0.248, and the LR + MR group (38.67 pg/ml ± 38.13, min: 10.15 pg/ml, max: 78.18 pg/ml), p = 0.096 ( • ▶ Fig. 4 ).
At the time of the second examination the mean level of AMH was lower in the HR group (0.96 ng/ml ± 0.81, min: 0.12 ng/ml, This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
max: 3.0 ng/ml) as compared to the fi rst analysis, the mean difference between them being Δ = 1.10 ng/ml ± 2.03, p = 0.03. In the LR + MR group, AMH values decreased to 2.68 ng/ml ± 2.47 (min: 0.71 ng/ml, max: 7.95 ng/ml), Δ = 1.42 ng/ml ± 2.38, p = 0.05 and were lower than in the control group (p = 0.027) ( • ▶ Fig. 1 ). FSH values increased in the HR group to 29.41 mIU/ml ± 42.86 (min: 2 mIU/ml, max: 78.2 mIU/ml), the diff erence between the fi rst and the second analysis being Δ = − 8.70 mIU/ml ± 28.22, p = 0.018. In the LR + MR group they did not change (7.45 mIU/ml ± 2.99, min: 4.51 mIU/ml, max: 13.7 mIU/ml), Δ = − 0.97 mIU/ml ± 3.28, p = 0.325 ( • ▶ Fig. 2 ). The mean values of LH were elevated in the HR group to 15.16 mIU/ml ± 13.30 (min: 2.58 mIU/ml, max: 42.7 mIU/ml), Δ = − 6.49 mIU/ml ± 9.47, p = 0.004, as well as in the LR + MR group (5.65 mIU/ml ± 3.23, min: 1.4 mIU/ml, max:
12.5 mIU/ml), Δ = − 1.46 mIU/ml ± 2.22, p = 0.044 ( • ▶ Fig. 3 ).
E2 levels remained unchanged in the HR group (35.59 pg/ ml ± 20.98, min: 11.06 pg/ml, max: 74.1 pg/ml), Δ = 9.96 pg/ ml ± 35.87, p = 0.435, and in the LR + MR group (31.84 pg/ ml ± 13.53, min: 22.9 pg/ml, max: 52.15 pg/ml), Δ = 7.51 pg/ ml ± 38.24, p = 0.51 ( • ▶ Fig. 4 ).
Abnormal (low and very low) AMH values (number and percentage) were found in the HR group (25 % and 35 %, respectively) in the fi rst examination. Very low AMH values were observed in 70 % of survivors at the time of the second examination. In the LR + MR group we found no survivors presenting very low AMH levels in the fi rst examination; however, they appeared in the second one (38 %). Similarly, elevated FSH levels > 2SD were observed in 30 % of HR patients at baseline and in 40 % in the second examination ( • ▶ Table 2 ).
We separated a group of survivors diagnosed with Hodgkin lymphoma. At the time of the fi rst analysis, we found normal values of AMH (2.96 ng/ml ± 2.05), FSH (6,88 mIU/ml ± 3.41), LH (3.83 mIU/ml ± 2.12), and E2 (47.24 pg/ml ± 31.60), whereas at the time of the second examination we observed a diff erence compared to the control: AMH was lower (1.26 ng/ml ± 0.84), p = 0.001, FSH increased to 9.64 mIU/ml ± 3.25 (p = 0.001). The mean level of LH did not change statistically (8.63 mIU/ml ± 9.44), p = 0.07 and E2 levels were comparable (40.08 pg/ml ± 18.09), p = 0.33. However, diff erences were noted between the fi rst and second examination: in Δ AMH values = 1.69 ng/ml ± 2.32, p = 0.022; in FSH values Δ = − 3.10 mIU/ml ± 3.97, p = 0.027; in LH levels Δ = − 4.89 mIU/ml ± 10.3, p = 0.033 and Δ E2 values 10.44 pg/ ml ± 37.54, p = 0.40 ( • ▶ Fig. 1 -4 ) .
Similarly, in patients diagnosed with solid tumours classifi ed for HR group we found lower AMH values than in LR + MR group at the time of the fi rst examination (0.50 ng/ml ± 0.19 vs. 4.64 ng/ ml ± 2.46, p = 0.009), and a tendency to lower values in the second examination (0.65 ng/ml ± 0.39 vs. 2.67 ng/ml ± 2.12, p = 0.064). LH values were elevated in the HR group (compared to the LR + MR group) at the time of the second examination (27.75 mIU/ ml ± 21.14 vs. 5.08 mIU/ml ± 3.15, p = 0.036). The values of FSH and E2 remained statistically unchanged ( • ▶ Fig. 1 -4 ). We observed no infl uence of age at treatment on the diff erences in hormone levels at the time of the fi rst and second analyses.
Discussion
▼
Gonadal damage, and in consequence infertility or impaired fertility, pose a problem for a signifi cant number of survivors. The risk of infertility depends on disease itself, its type, intensity and age at treatment. Although acute ovarian failure is rarely observed in childhood cancer survivors, the risk of developing premature menopause, with their various consequences such as metabolic syndrome, osteoporosis and psychosexual dysfunction, is 13-fold higher than that of siblings [ 10 , 11 ] . Based on the proposition made by Wallace et al., we divided our group according to the type of malignancy and treatment. This division into risk groups depends on gonadotoxicity of treatment (alkylating agents or/and radiotherapy to the pelvis, abdomen or total body irradiation) [ 5 ] . The results obtained were analysed from the low and median risk groups jointly due to a small number of patients classifi ed into the median risk group (4 survivors). The levels of AMH were measured as currently the best predictor for the follicular reserve. AMH is a product of growing follicles, from the stage of the primary follicle to the initial formation of the antrum . In healthy women, lowered AMH level can predict the time of future menopause [ 6 , 8 ] . Similarly, in women after gonadotoxic treatment, a fall in AMH levels indicates the degree of ovarian reserve depletion, even better than ultrasound measurement [ 12 , 13 ] . In healthy women, the levels of AMH are relatively constant from mid-childhood to early adulthood (from 8 to 25 year of age) [ 7 ] . Therefore, we compared our results from the fi rst and second examination with the same control group, in the same age range. At the time of the fi rst examination, performed 6-11 years after treatment termination, we found normal values of all study hormones in the low + median risk group. In the high risk group, the levels of AMH were lower than in the control and in the low + median risk group, and a tendency to higher (than in the control group) FSH levels (p = 0.053) was observed with simultaneously normal levels of estradiol. These fi ndings can indicate a poor ovarian reserve. The fi rst symptom, that is, a progressive increase in FSH, appears approximately 20 years prior to menopause, whereas the overt ones (elevated FSH and diminished AMH) are observed 4 years prior to menopause [ 14 -17 ] . The values of LH remained within the normal range, which results from premature ovarian failure [ 18 , 19 ] . In the HR group, 13 patients were diagnosed with HL. All of them received three or four cycles of MOPP and B-DOPA protocols with or without inverted Y irradiation to the infradiaphragmatic areas. Franchi-Rezqui et al. have suggested that the application of 3 or more MOPP cycles is suffi cient for premature ovarian failure (POF) [ 20 ] . Alkylating agents, especially procarbazine in a higher cumulative dose, are responsible for POF, whereas B-DOPA used for HL treatment does not exhibit a gonadotoxic eff ect. According to the results obtained by De Bruin et al., MOPP protocol is more toxic than irradiation to the paraaortic nodes, but the degree of toxicity rises when the fi eld of radiation includes the ovaries [ 21 ] . Behringer et al. have described a dose-dependent cytotoxic eff ect of alkylating agent indicating that acute toxicity provokes reduction in the number of follicles, whereas chronic toxicity leads to their premature atresia [ 22 ] . We found no infl uence of age at the time of treatment; all our patients after megachemotherapy and diagnosed with HL, except one, were treated in the pubertal period. Similarly, Hamre et al. and van Beek et al. did not demonstrate the infl uence of age at treatment (puberty, prepuberty) on hormone levels [ 18 , 23 ] , whereas De Bruin et al. in a large cohort (518 survivors aged 14-40 years at the time of diagnosis) observed a longer time to premature menopause in women treated at a younger age [ 21 , 24 ] . At the time of our fi rst analysis, the most serious hormonal disturbances were observed in patients after megachemotherapy as a conditioning before bone marrow transplantation (BMT) and in one patient subjected to pelvic irradiation (15 Gy) during childhood. Although Schuck et al. found the most serious and frequent ovarian failure in a young patient ( < 30 years of age) after irradiation of > 15 Gy directed to both ovaries, Wallace et al. determined LD 50 for the human oocytes to be < 2 Gy [ 25 , 26 ] . Li Fong et al., in the female group of cancer survivors after total body irradiation and high dose of cyclophosphamide, observed a signifi cant AMH decrease with increased FSH and amenorrhea [ 27 ] . Borgmann-Staudt et al. have indicated that treatment during puberty and high doses of busulphan are the principle risk factors for ovarian toxicity in women after BMT, whereas in men it is the treatment in the prepubertal period and total body irradiation (TBI) [ 28 ] . Treatment for solid tumours, with pelvis or spinal irradiation or/with alkylating agents, leads to POF [ 29 -31 ] . The hormonal analyses were repeated after the next 5 years and signifi cant changes were found in the investigated hormones. In all the HR group, the AMH levels (lower compared to the control group at the time of the fi rst examination) diminished twice (from x = 2.05 ng/ml to 0.96 ng/ml, Δ = 1.09 ng/ml), FSH rose (from x = 19.53 mIU/ml to 29.41 mIU/ml, Δ = − 8.70 mIU/ml) and LH (normal at fi rst measurement) was elevated (from x = 7.85 mIU/ ml to 15.15 mIU/ml, Δ = − 6.49 mIU/ml). In the LR + MR group, the hormone levels were comparable to the fi rst results, except for LH values which increased (from x = 8.67 mIU/ml to 15.16 mIU/ml, Δ = − 6.49 mIU/ml); however, the comparison of the second measurement with the control group indicated deterioration of AMH and FSH values. The increase noted between the fi rst and second analysis in the number (and percentage) of survivors presenting very low AMH values and elevated FSH levels in the HR group as well as elevated AMH levels in the LR + MR group indicates progressive deterioration of ovarian function and diminished ovarian reserve not only in the HR group but also in the LR + MR group. In HL survivors, as well as in patients treated for solid tumours classifi ed for HR group, the changes were similar to those in the total HR group. In our opinion, it is the fi rst prospective study presenting longtime ovarian function in young women treated previously (several years earlier) for cancer during childhood and adolescence. Our results suggest a serious loss of the primordial follicle pool and progressive ovarian failure, especially in the HR group. Brougham et al. made the prospective study in a group of female patients during and after treatment (12 months). In the low and median risk group they found a progressive AMH lowering at the time of treatment with recovery after 1 year, whereas in the HR group the recovery was not observed. They suggested the possibility of restoration of the pool of small growing follicles after less gonadotoxic therapy [ 24 ] . Morse et al. observed a group of female patients during and up to three years after cancer treatment and found the symptoms of ovarian damage at both time points, especially in patients radiated infradiaphragmatically or after BMT [ 32 ] . In our LR + MR group, the values of AMH lowered and FSH rose, thus indicating a decline in the number of oocytes, more accelerated than in healthy women. Taken together, our results show that after anticancer treatment the "fertility window" is shorter than in healthy women, particularly in the HR group. All patients, except for those after BMT and pelvic irradiation, presented normal menstrual cycles. Similarly, Larsen et al. have shown in cancer survivors with normal values of FSH and regular menses, a diminished number of small follicles and total number of follicles, thus suggesting that ovarian age is higher than chronological age. These regular menses can lead to misconception that ovarian potential is normal [ 29 ] . According to Childhood Cancer Survivor Study, the possibility of POF refers to 8 % of women, whereas in patients after more gonadotoxic treatment increases to 30 % [ 3 ] . This suggests the necessity of counselling among female cancer survivors on diminished ovarian reserve and the risk of premature menopause, as well as on the possibilities of fertility preservation. The analysis is limited by a small number of patients. We did not take into consideration the cumulative doses of gonadotoxic cytostatics, diff erent models of chemotherapy or the doses and areas of irradiation. We have now collected a group of 90 young women treated previously for diff erent cancers and we will continue this prospective study in a larger group. In conclusion, our fi ndings indicate that anticancer treatment during childhood and adolescence is associated with a serious, progressive risk of ovarian failure. It is necessary to inform female cancer survivors about the risk of premature menopause, especially those classifi ed into the high risk group.
